Skip to content

Dr. Gearóid Tuohy

Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Researchers at Moorfields Eye Hospital have reported valuable genotype-phenotype correlations on KCNV2-associated retinopathy  

Researchers have published a study showing that genetic missense alterations on KCNV2-asscociated retinopathy may appear to hold better visual acuity and greater structural integrity (Guimaraes… Read More »Researchers at Moorfields Eye Hospital have reported valuable genotype-phenotype correlations on KCNV2-associated retinopathy  

Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced its “first-in-patient” in a Phase 1/2 clinical trial for… Read More »Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.

Researchers at UCL and Moorfields Eye Hospital have reported an AI “foundation  model” for ophthalmology, published in the journal Nature.

Researchers at the Centre for Medical Image Computing, University College London, London, UK and the Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust,… Read More »Researchers at UCL and Moorfields Eye Hospital have reported an AI “foundation  model” for ophthalmology, published in the journal Nature.

Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy.